Adverse Events

Most common adverse reactions (≥5% of CIMZIA-treated patients and with a higher incidence compared to placebo) in controlled Crohn's clinical studies¹

Incidence of serious adverse events in CIMZIA clinical trials
(per 100 patient-years)¹

In completed and ongoing clinical studies^1*: CIMZIA, n=5118

• Tuberculosis: CIMZIA, 0.61 vs placebo, 0

In all clinical trials^1*: CIMZIA, n=4650; placebo, n=1319

• Malignancies: CIMZIA, 0.5 (0.4, 0.7)^† vs placebo, 0.6 (0.1, 1.7)^†

In CIMZIA RA clinical trials¹*: CIMZIA, n=2367

• A total of 3 cases of lymphoma were observed¹

*Including other investigational uses.
^†Numbers in parentheses represent a 95% confidence interval.

Reference:

1. CIMZIA [prescribing information]. Smyrna, GA: UCB, Inc.; 2009.